DLL3 and melanoma: On the other hand, high DLL3 expression was associated with poorer prognoses in melanomas (HR, 1.32; 95% CI, 1.22–1.44; P < 0.001), non-SCLCs (HR, 1.13; 95% CI, 1.09–1.18; P < 0.001), and female genital tract malignancies (HR, 1.24; 95% CI, 1.07–1.44; P = 0.004).